Birth Defects Associated with Valproic Acid
Valproic acid causes serious birth defects in approximately 10% of exposed pregnancies, with neural tube defects (particularly spina bifida) occurring in 1-2% of cases—representing a 10-20 fold increased risk compared to the general population. 1
Major Structural Malformations
The FDA drug label clearly identifies valproic acid as Pregnancy Category D, with the rate of congenital malformations being approximately four times higher than other antiseizure medications used as monotherapy 1. The most recent 2025 meta-analysis confirms these findings with specific relative risks 2:
Neural Tube Defects (Highest Risk)
- Spina bifida is the most characteristic defect (1-2% incidence vs. 0.06-0.07% baseline) 1
- Anencephaly occurs rarely 3
- RR = 6.54 (95% CI: 4.51-9.47) compared to other antiseizure medications 2
Cardiac Malformations
Craniofacial Defects
- Cleft lip and/or palate with RR = 4.31 (95% CI: 3.06-6.08) 2
- Characteristic facial dysmorphism including the "valproate syndrome" 3, 4
Genitourinary Anomalies
- Hypospadias (urethral opening abnormalities) 1
- Cryptorchidism (undescended testes) 4
- RR = 3.32 (95% CI: 2.67-4.14) 2
Musculoskeletal Defects
Fetal Valproate Syndrome
A recognizable pattern of abnormalities occurs even at low doses (500 mg/day), characterized by 4:
- Distinctive facial features (facial dysmorphism)
- Finger and limb abnormalities
- Developmental delays
- Decreased intrauterine growth 3
Critical caveat: The 2017 case series demonstrates these features occur without dose-dependence, affecting infants exposed to both low (500 mg/day) and high doses (1500 mg/day) 4.
Neurodevelopmental Effects
Beyond structural defects, the FDA label warns that children exposed to valproic acid in utero are at risk for lower IQ scores 1. The 2009 review documents:
- Decreased verbal intelligence
- Communication problems
- Autism spectrum disorder (ASD) manifestations 3
An observational study found 2.9 times increased risk (95% CI: 1.7-4.9) of autism spectrum disorders, with absolute risk of 4.4% in exposed children versus 1.5% in unexposed 1.
Dose-Related Considerations
While higher doses (≥1000 mg/day) carry greater risk 3, 6, the evidence shows malformations occur across all dose ranges 4. The 2024 Swedish cohort study of 17,996 children confirms valproic acid had "the strongest and most widespread associations with birth defects" among all antiseizure medications studied 7.
Clinical Management Imperatives
Valproic acid is absolutely contraindicated in pregnant women and women of childbearing potential unless no alternative exists 1. The FDA label explicitly states:
- Women who are pregnant must not take valproic acid to prevent migraine headaches 1
- All women of childbearing age must use effective contraception 1
- If unavoidable, use the lowest effective dose in 2-3 divided doses as monotherapy 3
- Periconceptional folic acid supplementation is mandatory (though it only partially reduces neural tube defect risk) 3, 6
The 2025 EudraVigilance analysis reveals that despite absolute contraindications and constant risk mitigation measures since 2018, pregnancy exposure to valproic acid continues to occur, with 2021 reports containing 3210 congenital disorders between 2013-2023 8.